

Vaccine safety is regarded as the absence of any serious adverse event following immunisation (sAEFI) in the vaccinated individual. The live oral poliovirus vaccine (OPV) causes an sAEFI—vaccine-associated paralytic polio (VAPP)—at a sufficiently low frequency (1 per 100 000 to 750 000 infants vaccinated with one or more doses), resulting in WHO declaring OPV to be safe for wide use.1,2 Thus, WHO, in effect, modified the standard definition of vaccine safety to be the absence of any sAEFI at an unacceptable frequency, thus introducing a subjective, arbitrary, element into the definition.
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet